FDA Approves Genentech Breast Cancer Treatment That Can Be Administered At Home
June 29 2020 - 2:05PM
Dow Jones News
By Stephen Nakrosis
The U.S. Food and Drug Administration on Monday said it approved
Genentech Inc.'s Phesgo, a treatment for breast cancer that can be
administered at home by a qualified health professional.
The FDA said Phesgo, which is a combination of pertuzumab,
trastuzumab and hyaluronidase, can be injected under the skin "to
treat adult patients with HER2-positive breast cancer that has
spread to other parts of the body, and for treatment of adult
patients with early HER2-positive breast cancer."
Phesgo is initially used in combination with chemotherapy, the
FDA said, adding qualified healthcare professionals can continue to
administer treatments at home when chemotherapy is completed.
"Currently, most patients with HER2-positive breast cancer
receive trastuzumab and pertuzumab at infusion centers. With a new
administration route, Phesgo offers an out-patient option for
patients to receive trastuzumab and pertuzumab," said Richard
Pazdur, director of the FDA's Oncology Center of Excellence and
acting director of the Office of Oncologic Diseases in the FDA's
Center for Drug Evaluation and Research.
Genentech Inc. is a Roche Holding AG company.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 29, 2020 13:50 ET (17:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
